SEARCH

SEARCH BY CITATION

Keywords:

  • Bcr-Abl kinase inhibitor;
  • AMN107;
  • imatinib;
  • acute lymphoblastic leukemia;
  • in vitro models

Abstract

BACKGROUND

Previous studies have shown that patients with Bcr-Abl–positive acute lymphoblastic leukemia (ALL) either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response.

METHODS

The authors investigated the effects of a newly designed Bcr-Abl inhibitor, AMN107, by comparing its in vitro inhibitory potency on p190 Bcr-Abl ALL cell lines with that of imatinib.

RESULTS

In two Philadelphia (Ph)-positive ALL cell lines, AMN107 was found to be 30–40 times more potent than imatinib in inhibiting cellular proliferation. AMN107 was also more effective than imatinib in inhibiting phosphorylation of p190 Bcr-Abl tyrosine kinase in cell lines and primary ALL cells. The inhibition of cellular proliferation was associated with the induction of apoptosis in only one of the cell lines. No activity was observed in cell lines lacking the BCR-ABL genotype.

CONCLUSIONS

The results of the current study suggest the superior potency of AMN107 compared with imatinib in Ph-positive ALL and support clinical trials of AMN107 in patients with Ph-positive ALL. Cancer 2005. © 2005 American Cancer Society.